Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $40.27 million versus the consensus estimate of $43.29 million.

Reaffirms FY12 outlook.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

Earnings Guidance